Drug Trial Radar · NCT05473910
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Jun 1, 2026
Study completion Jun 2028
Sponsor
- Lead sponsor
- TScan Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Conditions
- AML
- MDS
Interventions
SOC + TSC-101Drug
HA-2 positive or HA-1 negative
ControlOther
SOC alone
SOC + TSC-100Drug
HA-1 positive
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose limiting toxicitiesTime frame: 2 years
- Occurrence of adverse eventsTime frame: 2 years
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of Colorado - Anschutz Cancer Center
Aurora, Colorado
SCRI - Colorado Blood Cancer Institute
Denver, Colorado
Yale
New Haven, Connecticut
Memorial Cancer Institute
Hollywood, Florida
Moffitt Cancer Institute
Tampa, Florida
Northside Hospital
Atlanta, Georgia
Johns Hopkins University
Baltimore, Maryland
Mass General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute - Hematology/Oncology
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Columbia University
New York, New York
Mount Sinai
New York, New York
University North Carolina
Chapel Hill, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
SCRI - TriStar Bone Marrow Transplant
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Baylor University Medical Center
Dallas, Texas
MD Anderson
Houston, Texas
Froedert and Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.